ONCORED · An unrivalled medical device based on red- light photo biomodulation to prevent, improve and remove oral mucositis and dermatitis chemo radio induced as a side effect of cancer treatment

Today the healthcare system is under great pressure, suffering the challenges brought by cancer and the ageing of the population. Among these challenges is the need for treating oral mucositis (OM) and dermatitis. Both are considered as adverse effects of radio and chemo-therapy employed during the treatment of some cancers, specially leukaemia, head & neck cancers and breast cancers which only generate dermatitis. There is an increase incidence of cancers worldwide, for instance, 842,000 new cases of head and neck cancer were diagnosed in 2017. In addition, leukaemia counts with around 352,000 new cases diagnosed in 2015. And breast cancer is the second most common cancer with 1.7 million new cancer cases diagnosed in the year 2015. These inflammations, occur in 100% of patients that are receiving chemotherapy high‐dose. In views of the situation, there is an urgent need to treat these chemo and radio therapy-associated diseases but the current medical devices are ill adapted since the radiation emitted cannot be controlled in a homogenous way, resulting in an inefficient treatment of OM and dermatitis. In response, NEOMEDLIGHT have developed ONCORED, an innovative medical device based on photo biomodulation for the non-harmful treatment of oral mucositis and dermatitis. ONCORED seeks to simplify workflows at the clinical level enabling the prevention, improvement and removal of OM and dermatitis with homogenous red-light whose dose (energy and power) can be well controlled. Having validated the reliability of the ONCORED system at the pilot scale, we now want to finalise its development and achieve market preparedness. In Phase 1 we aim to carry a Feasibility Study to warrant the project from a technical, commercial and financial point of view. Besides the crucial benefits that it will bring to healthcare, ONCORED will boost the growth of NEOMEDLIGHT, expecting to gain € 27 million gross profit and 16 new people after 5 years in the market, reaching a ROI of 5.49.